GLOBAL BLOOD THERAPEUTICS IN's ticker is GBT and the CUSIP is 37890U108. A total of 208 filers reported holding GLOBAL BLOOD THERAPEUTICS IN in Q4 2021. The put-call ratio across all filers is 0.56 and the average weighting 0.3%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $156,946,000 | +1109.5% | 2,304,636 | +467.5% | 0.02% | +1050.0% |
| Q2 2022 | $12,976,000 | +102.2% | 406,113 | +119.2% | 0.00% | +100.0% |
| Q1 2022 | $6,417,000 | +28.6% | 185,230 | +8.7% | 0.00% | 0.0% |
| Q4 2021 | $4,990,000 | +271.3% | 170,456 | +223.3% | 0.00% | – |
| Q3 2021 | $1,344,000 | -33.8% | 52,722 | -9.0% | 0.00% | – |
| Q2 2021 | $2,029,000 | -93.3% | 57,919 | -92.3% | 0.00% | -100.0% |
| Q1 2021 | $30,505,000 | -0.1% | 748,623 | +6.2% | 0.00% | 0.0% |
| Q4 2020 | $30,531,000 | -13.8% | 704,945 | +7.4% | 0.00% | -33.3% |
| Q3 2020 | $35,408,000 | -24.4% | 656,435 | -11.5% | 0.01% | -33.3% |
| Q2 2020 | $46,845,000 | +99.2% | 742,034 | +61.2% | 0.01% | +50.0% |
| Q1 2020 | $23,522,000 | -31.9% | 460,383 | +5.9% | 0.01% | 0.0% |
| Q4 2019 | $34,553,000 | +65.3% | 434,690 | +0.9% | 0.01% | +50.0% |
| Q3 2019 | $20,902,000 | -3.3% | 430,795 | +7.6% | 0.00% | 0.0% |
| Q2 2019 | $21,614,000 | +6.9% | 400,466 | +4.8% | 0.00% | 0.0% |
| Q1 2019 | $20,223,000 | +32.6% | 382,069 | +2.9% | 0.00% | 0.0% |
| Q4 2018 | $15,249,000 | +10.9% | 371,448 | +2.6% | 0.00% | +33.3% |
| Q3 2018 | $13,752,000 | -3.0% | 361,865 | +15.4% | 0.00% | 0.0% |
| Q2 2018 | $14,179,000 | +163.0% | 313,677 | +180.9% | 0.00% | +200.0% |
| Q1 2018 | $5,392,000 | -38.8% | 111,650 | -50.1% | 0.00% | -50.0% |
| Q4 2017 | $8,809,000 | +28.4% | 223,879 | -3.8% | 0.00% | 0.0% |
| Q3 2017 | $6,862,000 | +6.5% | 232,621 | -1.3% | 0.00% | +100.0% |
| Q2 2017 | $6,446,000 | -22.0% | 235,675 | +5.1% | 0.00% | -50.0% |
| Q1 2017 | $8,262,000 | +225.3% | 224,207 | +27.5% | 0.00% | +100.0% |
| Q4 2016 | $2,540,000 | -40.5% | 175,825 | -5.1% | 0.00% | 0.0% |
| Q3 2016 | $4,272,000 | +45.6% | 185,305 | +4.8% | 0.00% | 0.0% |
| Q2 2016 | $2,935,000 | -0.5% | 176,855 | -4.9% | 0.00% | 0.0% |
| Q1 2016 | $2,950,000 | -51.3% | 186,000 | -0.8% | 0.00% | -50.0% |
| Q4 2015 | $6,062,000 | -32.7% | 187,500 | -12.2% | 0.00% | 0.0% |
| Q3 2015 | $9,005,000 | – | 213,575 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 595,473 | $25,790,000 | 4.19% |
| Grace Capital | 131,549 | $5,697,000 | 3.60% |
| Fernwood Investment Management, LLC | 201,657 | $8,734,000 | 3.44% |
| Fairmount Funds Management LLC | 215,000 | $9,312,000 | 3.33% |
| Arctis Global LLC | 293,700 | $12,720,000 | 2.74% |
| Perceptive Advisors | 5,674,711 | $245,771,000 | 2.64% |
| ArchPoint Investors | 217,510 | $9,420,000 | 2.61% |
| Alerce Investment Management, L.P. | 126,270 | $5,469,000 | 2.15% |
| Profit Investment Management, LLC | 42,196 | $1,826,000 | 1.17% |
| Affinity Asset Advisors, LLC | 50,000 | $2,166,000 | 1.15% |